<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961297</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 09-1156</org_study_id>
    <secondary_id>R01DC012545</secondary_id>
    <nct_id>NCT01961297</nct_id>
  </id_info>
  <brief_title>Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response</brief_title>
  <official_title>Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristina Simonyan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research aims to determine brain abnormalities in patients with spasmodic
      dysphonia (SD) and voice tremor (VT) as the basis for characterization of central mechanisms
      underlying symptom improvement following the use of sodium oxybate, a novel oral medication
      for the treatment of ethanol-responsive dystonia. The proposed research is relevant to public
      health because the elucidation of disorder-specific mechanistic aspects of brain organization
      in SD vs. SD/VT is ultimately expected to lead to establishment of enhanced criteria for
      clinical management of these disorders, including differential diagnosis and treatment. Thus,
      the proposed research is relevant to the part of NIH's mission that pertains to developing
      fundamental knowledge that will help to reduce the burdens of human disability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spasmodic dysphonia (SD) is a chronic debilitating condition, characterized by selective loss
      of voluntary voice control during speech production due to uncontrolled spasms in the
      laryngeal muscles. SD becomes even more incapacitating when it is associated with
      action-induced voice tremor (VT) due to its poor response to gold standard treatment with
      botulinum toxin. There is, therefore, a critical need to identify new treatment opportunities
      for SD/VT patients who receive limited, if any, benefits from botulinum toxin injections. The
      design and use of novel therapeutic approaches for these patients will, however, be largely
      unattainable if the central mechanisms of SD and VT development remain unknown. Our long-term
      goal is to determine the pathophysiology of SD and related disorders, such as VT, for the
      development of new diagnostic and treatment options for these patients. The objective of this
      application is to identify brain abnormalities in SD and SD/VT patients as the basis for
      characterization of central mechanisms underlying symptom improvement following the use of
      sodium oxybate, a novel pharmacological agent for treatment of ethanol-responsive dystonia.
      Our central hypothesis is that, compared to SD patients, SD/VT patients will have additional
      brain abnormalities within the sensorimotor brain circuits controlling voice production,
      which are being modulated to a greater extent with sodium oxybate treatment. We further
      postulate that clinical efficacy of sodium oxybate treatment will correlate with its central
      modulatory effects. The rationale for the proposed research is that identification of
      distinct brain mechanisms underlying SD and SD/VT clinical manifestations would provide the
      necessary insights into the pathophysiology of these disorders, while understanding the
      neural correlates of sodium oxybate action would allow establishment of a scientific
      rationale for the use of a novel treatment in these disorders. Using a comprehensive approach
      of multi-modal neuroimaging and clinico-behavioral testing, our central hypothesis will be
      tested by pursuing two specific aims: (1) determine disorder-specific brain abnormalities in
      SD and SD/VT patients, and (2) characterize the central effects of sodium oxybate treatment
      in ethanol-responsive SD and SD/VT patients. This research is innovative because it focuses
      not only on identification of distinct pathophysiological factors contributing to SD and VT
      development, but also on discovery of mechanisms of central effects of a novel oral
      medication, sodium oxybate, which holds promise for treatment of refractory symptoms in SD
      and SD/VT. The proposed research is significant because it will advance our understanding of
      the pathophysiology of dystonia in general and SD in particular as well as will have direct
      impact on improvement of clinical management of SD and SD/VT patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Reported Positive Effects.</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants who had reported positive effects of at least one alcohol drink on their voice symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Voice Breaks</measure>
    <time_frame>baseline and Day 1</time_frame>
    <description>The number of SD-characteristic voice breaks in each sentence at pre-drug and post-drug assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice Harshness Severity</measure>
    <time_frame>baseline and Day 1</time_frame>
    <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathlessness Severity</measure>
    <time_frame>baseline and Day 1</time_frame>
    <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice Tremor Severity</measure>
    <time_frame>baseline and Day 1</time_frame>
    <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Spasmodic Dysphonia</condition>
  <condition>Voice Tremor</condition>
  <arm_group>
    <arm_group_label>Sodium oxybate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium oxybate</intervention_name>
    <description>Sodium oxybate</description>
    <arm_group_label>Sodium oxybate</arm_group_label>
    <other_name>Xyrem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically documented diagnosis of SD and/or VT with positive effects of alcohol on
             their symptoms;

          -  Age from 21 to 80 years;

          -  Native English speakers;

          -  Right-handedness (based on Edinburgh Handedness Inventory).

        Exclusion Criteria:

          -  Subjects who are incapable of giving an informed consent;

          -  Pregnant and breastfeeding women until a time when they are no longer pregnant or
             breastfeeding will be excluded from the study. All patients of childbearing potential
             will be required to agree to use a reliable method of contraception prior and during
             the treatment with sodium oxybate and prior to receiving botulinum toxin. The method
             of contraception will be documented in the patient's research chart. All women of
             childbearing potential will undergo a urine pregnancy test, which must be negative for
             study participation;

          -  Subjects with past or present medical history of

               1. any neurological disorders, except for spasmodic dysphonia and voice tremor, will
                  be excluded from the study in order to maintain the homogenous patient
                  population, allow for the evaluation of drug effect on CNS without confounding by
                  the presence of other neurological conditions, and identify SD and VT
                  disorder-specific changes in brain function and structure. Patients who report
                  other past or present neurological problems, such as stroke, movement disorders
                  other than SD and VT, brain tumors, traumatic brain injury with loss of
                  consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases,
                  alcoholism, drug dependence will be excluded. As voice tremor is one of the forms
                  of essential tremor, patients with moderate to severe essential tremor affecting
                  other body parts will be excluded from the study. All patients who have dystonic
                  movements in other than larynx body regions will also be excluded from the study;

               2. psychiatric problems, such as schizophrenia, major and/or bipolar depression,
                  obsessive-compulsive disorder, will be excluded to maintain the homogenous
                  patient population, allow for the evaluation of drug effect on CNS without
                  confounding by the presence of psychiatric conditions and identify
                  disorder-specific changes in brain function and structure;

               3. laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and
                  polyps, carcinoma, chronic laryngitis;

               4. known past or present history of grade 2 or higher hepatic and renal dysfunction
                  according to the NCI criteria.;

               5. known past or present history of moderate to severe congestive heart failure;

               6. known past or present history of cognitive impairment and active suicidal
                  ideations;

          -  Patients who are not symptomatic due to treatment with botulinum toxin injections into
             the laryngeal muscles. The duration of positive effects of botulinum toxin vary from
             patient to patient but lasts on average for 3-4 months. All patients will be evaluated
             to ensure that they are fully symptomatic prior to the entering the study, except the
             substudy, which will examine the effects of combined botulinum toxin and sodium
             oxybate treatments on abnormal brain function in SD and VT patients;

          -  To avoid the possibility of confounding effects of drugs acting upon the central
             nervous system, all study participants will be questioned about any prescribed or
             over-the-counter medications as part of their initial intake screening. Those patients
             who receive medication(s) affecting the central nervous system (except sodium oxybate)
             will be excluded from the study.

          -  The participants will be asked whether they have undergone any head and neck
             surgeries, particularly any brain surgery and laryngeal surgeries, such as
             thyroplasty, laryngeal denervation, and selective laryngeal adductor
             denervation-reinnervation. Because both brain and laryngeal surgery may potentially
             lead to the brain structure and function re-organization, all subjects with history of
             brain and/or laryngeal surgery will be excluded from the study.

          -  The subjects who have tattoos, ferromagnetic objects in their bodies (e.g., implanted
             stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that cannot be
             removed for the purpose of MRI study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Simonyan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Simonyan K, Frucht SJ. Long-term Effect of Sodium Oxybate (XyremÂ®) in Spasmodic Dysphonia with Vocal Tremor. Tremor Other Hyperkinet Mov (N Y). 2013 Dec 9;3. pii: tre-03-206-4731-1. doi: 10.7916/D8CJ8C5S. eCollection 2013.</citation>
    <PMID>24386608</PMID>
  </reference>
  <results_reference>
    <citation>Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of sodium oxybate in Spasmodic dysphonia. Laryngoscope. 2017 Jun;127(6):1402-1407. doi: 10.1002/lary.26381. Epub 2016 Nov 3.</citation>
    <PMID>27808415</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>September 29, 2017</results_first_submitted>
  <results_first_submitted_qc>October 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 22, 2017</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Kristina Simonyan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dystonia</keyword>
  <keyword>tremor</keyword>
  <keyword>treatment</keyword>
  <keyword>sodium oxybate</keyword>
  <keyword>brain activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>75 subjects were consented, some did not meet criteria, and 53 were enrolled into the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Spasmodic Dysphonia</title>
          <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
        </group>
        <group group_id="P2">
          <title>Spasmodic Dysphonia/Voice Tremor</title>
          <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>unconfirmed diagnosis of SD</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Spasmodic Dysphonia</title>
          <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
        </group>
        <group group_id="B2">
          <title>Spasmodic Dysphonia/Voice Tremor</title>
          <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="11.3"/>
                    <measurement group_id="B2" value="58.0" spread="12.2"/>
                    <measurement group_id="B3" value="54.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dystonia subtype</title>
          <description>ABSD = abductor spasmodic dysphonia; ADSD = adductor spasmodic dysphonia; VT = voice tremor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ADSD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABSD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADSD/VT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABSD/VT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset of dysphonia</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="11.0"/>
                    <measurement group_id="B2" value="44.1" spread="14.2"/>
                    <measurement group_id="B3" value="40.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of symptom of dysphonia</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.4" spread="11.5"/>
                    <measurement group_id="B2" value="14.7" spread="12.7"/>
                    <measurement group_id="B3" value="14.1" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spasmodic dysphonia severity</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="16.3"/>
                    <measurement group_id="B2" value="30.3" spread="16.8"/>
                    <measurement group_id="B3" value="28.0" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Voice Tremor severity</title>
          <description>Only for participants that had voice tremor (VT). VT symptoms were evaluated using a visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
          <population>Only participants with voice tremor (VT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="49.3" spread="24.7"/>
                    <measurement group_id="B3" value="49.3" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported Positive Effects.</title>
        <description>Number of participants who had reported positive effects of at least one alcohol drink on their voice symptoms</description>
        <time_frame>Day 1</time_frame>
        <population>Only alcohol-responsive participants were in this analysis which is 23 from the SD group and 22 from the SD/VT group.</population>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
          <group group_id="O2">
            <title>Spasmodic Dysphonia/Voice Tremor</title>
            <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Positive Effects.</title>
          <description>Number of participants who had reported positive effects of at least one alcohol drink on their voice symptoms</description>
          <population>Only alcohol-responsive participants were in this analysis which is 23 from the SD group and 22 from the SD/VT group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Voice Breaks</title>
        <description>The number of SD-characteristic voice breaks in each sentence at pre-drug and post-drug assessment</description>
        <time_frame>baseline and Day 1</time_frame>
        <population>Only alcohol-responsive participants were included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
          <group group_id="O2">
            <title>Spasmodic Dysphonia/Voice Tremor</title>
            <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Voice Breaks</title>
          <description>The number of SD-characteristic voice breaks in each sentence at pre-drug and post-drug assessment</description>
          <population>Only alcohol-responsive participants were included in analysis</population>
          <units>voice breaks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.6"/>
                    <measurement group_id="O2" value="4.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.8"/>
                    <measurement group_id="O2" value="2.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Voice Harshness Severity</title>
        <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
        <time_frame>baseline and Day 1</time_frame>
        <population>Only alcohol-responsive participants were included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
          <group group_id="O2">
            <title>Spasmodic Dysphonia/Voice Tremor</title>
            <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
        </group_list>
        <measure>
          <title>Voice Harshness Severity</title>
          <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
          <population>Only alcohol-responsive participants were included in analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="25.3"/>
                    <measurement group_id="O2" value="58.3" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="23.6"/>
                    <measurement group_id="O2" value="31.6" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breathlessness Severity</title>
        <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
        <time_frame>baseline and Day 1</time_frame>
        <population>Only alcohol-responsive participants were included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
          <group group_id="O2">
            <title>Spasmodic Dysphonia/Voice Tremor</title>
            <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
        </group_list>
        <measure>
          <title>Breathlessness Severity</title>
          <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
          <population>Only alcohol-responsive participants were included in analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="18.1"/>
                    <measurement group_id="O2" value="18.6" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="19.5"/>
                    <measurement group_id="O2" value="14.8" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Voice Tremor Severity</title>
        <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
        <time_frame>baseline and Day 1</time_frame>
        <population>Only alcohol-responsive participants with voice tremors were included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Spasmodic Dysphonia</title>
            <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
          <group group_id="O2">
            <title>Spasmodic Dysphonia/Voice Tremor</title>
            <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
          </group>
        </group_list>
        <measure>
          <title>Voice Tremor Severity</title>
          <description>Visual analog scale of severity (0 for none, 100 for most severe/profound)</description>
          <population>Only alcohol-responsive participants with voice tremors were included in analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="51.2" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="31.4" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 60 minutes after drug ingestion</time_frame>
      <desc>side effects questionnaire, Epworth Sleepiness Scale</desc>
      <group_list>
        <group group_id="E1">
          <title>Spasmodic Dysphonia</title>
          <description>Participants with Spasmodic Dysphonia (SD) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
        </group>
        <group group_id="E2">
          <title>Spasmodic Dysphonia/Voice Tremor</title>
          <description>Participants with Spasmodic Dysphonia/Voice Tremor (SD/VT) given oral administration of a single dose of sodium oxybate (1.0-1.5 gm)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Slight lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of this study was reliance on patients' self-reports of alcohol response.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kristina Simonyan</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-0656</phone>
      <email>kristina.simonyan@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

